TuHURA Biosciences (HURA) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 24.0% versus a loss of 67.6%. Over five years, HURA leads with a -99.9% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($125.2 million vs $124.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | TNXP |
|---|---|---|
| Share price | $1.96 | $7.30 |
| Market cap | $124.90M | $125.20M |
| 1-day change | +1.55% | +0.27% |
| YTD return | +158.92% | -53.27% |
| 1-year return | -24.03% | -67.61% |
| 5-year return | -99.87% | -100.00% |
| EPS (TTM) | $-0.54 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $22.38 |
| 52-week low | $0.41 | $7.10 |
| Distance from 52-week high | -42.86% | -67.38% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +310.20% | +509.59% |
| Average volume | 245.98K | 542.97K |
| Shares outstanding | 63.73M | 17.15M |
| Employees | 22 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed TNXP by 43.6 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
HURA vs TNXP FAQ
Which is bigger, TuHURA Biosciences or Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $125.20M compared with $124.90M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or TNXP?
HURA returned -24.03% over the past 12 months, compared with -67.61% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.